Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 09/02 04:00:01 pm
359.5 USD   +2.58%
2h agoDJMARKET SNAPSHOT : S&P 500 Falls Back Under 2,000 As Stocks Slip
4h ago S&P 500 MOVERS : Wynn, spls
4h ago NASDAQ 100 MOVERS : Wynn, spls
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Assigned Patent

12/31/2013 | 03:06am US/Eastern
Recommend:
0

By Targeted News Service

ALEXANDRIA, Va., Dec. 31 -- Regeneron Pharmaceuticals, Tarrytown, N.Y., has been assigned a patent (8,613,927) developed by five co-inventors for a "high affinity human antibodies to human nerve growth factor." The co-inventors are Lynn MacDonald, White Plains, N.Y., Richard Torres, New York, Marc R. Morra, Beacon Falls, Conn., Joel H. Martin, Putnam Valley, N.Y., and Joel C. Reinhardt, Mount Kisco, N.Y.

The patent application was filed on Feb. 28, 2012 (13/406,734). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=3&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=141&f=G&l=50&co1=AND&d=PTXT&s1=20131224.PD.&s2=%28NY.ASST.%29&OS=ISD/12/24/2013+AND+AS/NY&RS=ISD/12/24/2013+AND+AS/NY

Written by Sudarshan Harpal; edited by Jaya Anand.

SH1231JA1231-963857

© Targeted News Service, Acquiremedia 2014
Recommend :
0
React to this article
Latest news on REGENERON PHARMACEUTICALS
2h agoDJMARKET SNAPSHOT : S&P 500 Falls Back Under 2,000 As Stocks Slip
4h ago S&P 500 MOVERS : Wynn, spls
4h ago NASDAQ 100 MOVERS : Wynn, spls
5h agoDJMARKET SNAPSHOT : S&P 500 Dips, But Apple, Staples, Tesla Pop
6h agoDJMARKET SNAPSHOT : S&P 500 Flat After ISM Data; Staples, Regeneron Pop
7h ago REGENERON PHARMACEUTICALS : Sanofi : and Regeneron Present Detailed Positive Res..
1d ago Pricing is key for new heart drugs challenging cheap generics
5d ago REGENERON PHARMACEUTICALS : Assigned Patent
08/25 NASDAQ 100 MOVERS : Intu, gild
08/20 REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations for I..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF